Cell therapy startup Immusoft lands deal with Takeda worth potentially more than $900M
GeekWire
OCTOBER 14, 2021
Under the agreement, Takeda has options to exclusively license programs at the preclinical stage and will take products to the clinic and through commercialization. Immusoft’s most advanced therapeutic program is designed to treat a rare enzyme deficiency disorder, Hurler syndrome.
Let's personalize your content